{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:28:50Z","timestamp":1792610930080,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1053\/j.ackd.2012.07.012","type":"journal-article","created":{"date-parts":[[2012,10,23]],"date-time":"2012-10-23T07:05:43Z","timestamp":1350975943000},"page":"404-412","source":"Crossref","is-referenced-by-count":2,"title":["The Rheumatology of Gout"],"prefix":"10.1053","volume":"19","author":[{"given":"John S.","family":"Sundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2012.07.012_bib1","series-title":"Gout and Hyperuricemia","author":"Wyngaarden","year":"1976"},{"key":"10.1053\/j.ackd.2012.07.012_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00296-009-1002-8","article-title":"Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved","volume":"30","author":"Thiele","year":"2010","journal-title":"Rheumatology Int"},{"key":"10.1053\/j.ackd.2012.07.012_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/0003-4819-64-2-229","article-title":"Allopurinol in the treatment of gout","volume":"64","author":"Rundles","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib6","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2012.07.012_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2369-12-36","article-title":"Chronic kidney disease in gout in a managed care setting","volume":"12","author":"Fuldeore","year":"2011","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ackd.2012.07.012_bib11","first-page":"562","article-title":"Medication errors with the use of allopurinol and colchicine: a retrospective study of a national, anonymous Internet-accessible error reporting system","volume":"33","author":"Mikuls","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","article-title":"Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD)","volume":"44","author":"Mikuls","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.ackd.2012.07.012_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.ackd.2012.07.012_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib15","series-title":"Kelley's Textbook of\u00a0Rheumatology","article-title":"Gout and Hyperuricemia","author":"Wortmann","year":"2009"},{"key":"10.1053\/j.ackd.2012.07.012_bib16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/rheumatology\/kem058","article-title":"Diagnosis of gout by ultrasound","volume":"46","author":"Thiele","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.ackd.2012.07.012_bib17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/BOR.0b013e3282f4eff5","article-title":"Refractory gout: what is it and what to do about it?","volume":"20","author":"Fels","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2012.07.012_bib19","first-page":"1923","article-title":"Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout","volume":"32","author":"Alvarez-Nemegyei","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib20","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3111\/13696998.2010.540874","article-title":"Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy","volume":"14","author":"Edwards","year":"2011","journal-title":"J Med Econ"},{"key":"10.1053\/j.ackd.2012.07.012_bib22","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1681\/ASN.2007111256","article-title":"Association of incident gout and mortality in dialysis patients","volume":"19","author":"Cohen","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2012.07.012_bib23","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2169\/internalmedicine.44.706","article-title":"Frequency of gouty arthritis in patients with end-stage renal disease in Japan","volume":"44","author":"Ohno","year":"2005","journal-title":"Intern Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib24","first-page":"385","article-title":"The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study","volume":"9","author":"Shelmadine","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1053\/j.ackd.2012.07.012_bib25","unstructured":"Zyloprim Prescribing Information. 2012. Available at: http:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?id=13564-nlm34068-7. Accessed June 2,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib26","unstructured":"Uloric Prescribing Information. 2012. Available at: http:\/\/www.uloric.com. Accessed June 2,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib27","unstructured":"Krystexxa TM Prescribing Information. 2012. Available at: http:\/\/krystexxa.com\/pdfs\/KRYSTEXXA_Prescribing_Information.pdf. Accessed April 15,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib28","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2215\/CJN.00670111","article-title":"Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population","volume":"6","author":"Latif","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2012.07.012_bib29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000151292","article-title":"Low serum uric acid level is a risk factor for death in incident hemodialysis patients","volume":"29","author":"Lee","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2012.07.012_bib30","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000168484","article-title":"Serum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patients","volume":"29","author":"Tang","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2012.07.012_bib31","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1093\/ndt\/gfp272","article-title":"Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients","volume":"24","author":"Park","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2012.07.012_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/BOR.0b013e3283361ac0","article-title":"Unusual clinical presentations of gout","volume":"22","author":"Ning","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib33","doi-asserted-by":"crossref","unstructured":"Forbess LJ, Fields TR. The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi. Semin Arthritis Rheum. doi:10.1016\/j.semarthrit.2012.03.007.","DOI":"10.1016\/j.semarthrit.2012.03.007"},{"key":"10.1053\/j.ackd.2012.07.012_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3171\/spi.2005.2.2.0215","article-title":"Topacheous gout as a rare cause of spinal stenosis in the lumbar region. Case report","volume":"2","author":"Kelly","year":"2005","journal-title":"J Neurosurg Spine"},{"key":"10.1053\/j.ackd.2012.07.012_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1756-185X.2010.01565.x","article-title":"Tophaceous gout of the odontoid process causing glossopharyngeal, vagus, and hypoglossal nerve palsies","volume":"14","author":"Tran","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"10.1053\/j.ackd.2012.07.012_bib36","first-page":"15","article-title":"Spinal gout mimicking paraspinal abscess: a case report","volume":"4","author":"Udayakumar","year":"2010","journal-title":"J Radiol Case Rep"},{"key":"10.1053\/j.ackd.2012.07.012_bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0303-8467(05)80010-1","article-title":"Sudden hypotonic paraparesis caused by tophaceous gout of the lumbar spine","volume":"93","author":"Vervaeck","year":"1991","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1053\/j.ackd.2012.07.012_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1161\/01.CIR.67.3.699","article-title":"Pulmonic regurgitation due to valvular tophi","volume":"67","author":"Curtiss","year":"1983","journal-title":"Circulation"},{"key":"10.1053\/j.ackd.2012.07.012_bib39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/jcp.38.8.873","article-title":"Aortic valvular tophus: identification by X-ray diffraction of urate and calcium phosphates","volume":"38","author":"Gawoski","year":"1985","journal-title":"J Clin Pathol"},{"key":"10.1053\/j.ackd.2012.07.012_bib40","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/BF03347542","article-title":"A rare and asymptomatic case of mitral valve tophus associated with severe gouty tophaceous arthritis","volume":"27","author":"Iacobellis","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.1053\/j.ackd.2012.07.012_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib42","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2012.07.012_bib43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ackd.2012.07.012_bib45","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib46","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib47","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2012.07.012_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.ackd.2012.07.012_bib49","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.ackd.2012.07.012_bib50","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.ackd.2012.07.012_bib51","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.ackd.2012.07.012_bib52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib53","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/ndt\/gfr060","article-title":"HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency","volume":"26","author":"Jung","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2012.07.012_bib54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/clpt.2011.113","article-title":"Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level","volume":"90","author":"Stamp","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ackd.2012.07.012_bib55","doi-asserted-by":"crossref","unstructured":"Stamp LK, Barclay ML, O'Donnell JL, et\u00a0al. Furosemide increases plasma oxypurinol without lowering serum urate\u2014a complex drug interaction: implications for clinical practice. Rheumatology (Oxford). doi:10.1093\/rheumatology\/kes091.","DOI":"10.1093\/rheumatology\/kes091"},{"key":"10.1053\/j.ackd.2012.07.012_bib56","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib57","unstructured":"Probenecid Prescribing Information. 2003. Available at: http:\/\/pi.watson.com\/data_stream.asp?product_group=1301&p=pi&language=E. Accessed July 22,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib58","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ackd.2012.07.012_bib59","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1053\/j.ackd.2012.07.012_bib60","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","article-title":"PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment","volume":"23","author":"Hoshide","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1053\/j.ackd.2012.07.012_bib61","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1053\/j.ackd.2012.07.012_bib62","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1053\/j.ackd.2012.07.012_bib63","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib64","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.taap.2006.08.004","article-title":"Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?","volume":"217","author":"Decleves","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1053\/j.ackd.2012.07.012_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0006-2952(96)00693-4","article-title":"Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation","volume":"53","author":"Tateishi","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/j.ackd.2012.07.012_bib67","unstructured":"Colcrys Prescribing Information. 2012. Available at: http:\/\/www.colcrys.com\/assets\/pdf\/COLCRYS_Full_Prescribing_Information.pdf. Accessed June 2,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib68","unstructured":"U.S. Food and Drug Administration. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). 2009. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174315.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=colchicinedrugsafetycommunications&utm_content=2. Accessed June 9,\u00a02012."},{"key":"10.1053\/j.ackd.2012.07.012_bib69","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1053\/j.ackd.2012.07.012_bib70","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ackd.2012.07.012_bib71","doi-asserted-by":"crossref","unstructured":"Schumacher HR Jr, Evans RR, Saag KG, et\u00a0al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results of the presurge-1 trial. Arthritis Care Res (Hoboken). doi:10.1002\/acr.21690.","DOI":"10.1002\/acr.21690"},{"key":"10.1053\/j.ackd.2012.07.012_bib72","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/art.33412","article-title":"Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial","volume":"64","author":"Schumacher","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.ackd.2012.07.012_bib73","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1\u00a0inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ackd.2012.07.012_bib74","doi-asserted-by":"crossref","unstructured":"Schlesinger N, Alten RE, Bardin T, et\u00a0al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. doi:10.1136\/annrheumdis-2011-200908.","DOI":"10.1136\/annrheumdis-2011-200908"},{"key":"10.1053\/j.ackd.2012.07.012_bib75","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar3297","article-title":"Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study","volume":"13","author":"Schlesinger","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.ackd.2012.07.012_bib76","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.ackd.2012.07.012_bib77","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559512001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559512001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T19:25:25Z","timestamp":1542655525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559512001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":77,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1548559512001498"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2012.07.012","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}